
Truveta brand logo mark in teal on a black background, featuring stacked chevron shapes forming the Truveta symbol.
Close

Research

Featured research

Truveta research graphic titled '2026 Cyclosporiasis Outbreak: Diagnoses Reach Historic Levels,' featuring outbreak trend lines that illustrate a significant rise in cyclospora diagnoses during summer 2026

Cyclosporiasis diagnoses reach historic levels in 2026 summer outbreak

During July 2026, the rate of cyclosporiasis diagnosis reached 10.5 per 100,000 people with a healthcare encounter, more than 11-fold higher than the average July rate observed between 2018 and 2025 (0.9 per 100,000). More than 1 in 5 patients with a cyclosporiasis...
Read More
early uptake of GLP-1 Foundayo pill for obesity

Early uptake of oral orforglipron (Foundayo pill) for obesity following FDA approval

More than 2 in 5 patients (40.3%) initiating oral orforglipron (Foundayo pill) had no prior evidence of GLP-1-based medication use, suggesting early uptake extends beyond patients already receiving injectable therapies. Among patients with prior GLP-1-based medication...
Read More
Truveta graphic promoting research on e-bike and e-scooter injuries, featuring the headline "E-bike and e-scooter injuries rising rapidly" with a subtitle highlighting increasing emergency department visits among children and adolescents over a background line chart of injury trends.

Emergency department visits related to e-bike and e-scooter injuries are rising rapidly among children and adolescents

Truveta Research finds e-bike and e-scooter injury ED visits rose 7.5-fold among children, with head and neck injuries most common.

Read More

Featured research topics

GLP-1

Oncology

Flu/RSV

Measles

Cardiovascular